DIADEM SpA

📍 London, United Kingdom🗓 Founded 2012👥 4 employees💰 Last funded Mar 2022
Biotechnology🌐 DIADEMDX.COM
Website LinkedIn
Diadem’s goal is to be the first truly blood-based Prognostic (Px) test for early detection of dementia in Neurodegenerative disease with a particular focus to Alzheimer’s Disease. Diadem has developed a unique/novel solution to one of the biggest problems in Neurodegenerative disease and in particular in early, accurate, predictive, fast, non-invasive and cost effective diagnosis in Alzheimer’s disease, which should enable improve treatment and the overall improvement in patient treatment/outcomes. Diadem was founded in 2012 as a spin-off of University of Brescia (Italy) and preparing for rapid commercialisation of its product via a global launch with strategic partners in 2021, additionally the Company is planning to carrying out further retrospective and prospective clinical trials to further validate its clinical claims.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2012
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Italy
1
Frequently asked questions
Who invested in DIADEM SpA?
DIADEM SpA has 1 investors on record on gritt.io and 1 late-stage investors.
When did DIADEM SpA last raise funding?
The most recent investment in DIADEM SpA recorded on gritt.io was in March 2022.
When was DIADEM SpA founded?
DIADEM SpA was founded in 2012.
What industry is DIADEM SpA in?
DIADEM SpA operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is DIADEM SpA based?
DIADEM SpA is headquartered in London, United Kingdom.